Why Novo Nordisk Is Dropping Its Collaboration with Hims & Hers
Novo Nordisk is ending its partnership with Hims & Hers due to concerns over its practices related to compounded GLP-1s.
Following Novo Nordisk, Eli Lilly Lands Partner for R&D of Longer-Acting Metabolic Meds
Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology to its metabolic medicines; the deal follows a similar move Novo Nordisk starting an alliance with Ascendis.
The Role of Consultants in Tackling Healthcare Expenses
To ensure effective cost mitigation, employers can’t wait for the market to adjust — they have to punch first.
Details From Head-to-Head Phase 3 Test Give Fuller Picture of Zepbound’s Edge Over Wegovy
Eli Lilly reported that in addition to achieving greater reductions in weight, Zepbound-treated patients achieved greater reductions in waist circumference compared to those treated with Novo Nordisk’s Wegovy. Full details from the head-to-head Phase 3 test were presented at the European Congress on Obesity meeting.
Novo Nordisk Forms GLP-1 Partnership with Hims & Hers
Hims & Hers is now offering discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, on its platform.
Novo Nordisk Notches a Court Win Against Wegovy and Ozempic Compounders
A federal court judge ruling leaves in place an FDA determination that shortages of the Novo Nordisk drugs Wegovy and Ozempic are resolved. Consequently, compounding pharmacies must stop making their versions of the metabolic medicines or face FDA enforcement action.
Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s
Novo Nordisk gets global rights to Lexicon Pharmaceuticals’ LX9851, an oral small molecule with a first-in-class approach to sparking weight loss. The licensing agreement comes months after Lexicon reported encouraging preclinical data from tests of LX9851 in combination with semaglutide, the main ingredient in Novo Nordisk’s Wegovy.
5 Strategic Steps To Bring Your Email Security Up To Today’s Standards
This report highlights what Paubox says is a broken infrastructure at the heart of this issue, exposing millions to preventable risks.
Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases
Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies.
Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss
CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound.
Novo Nordisk Launches Lower-Cost Wegovy, Following Eli Lilly Into Direct-to-Patient Sales
Wegovy will ship directly to eligible patients through NovoCare, an online pharmacy established by Novo Nordisk. The product’s price matches a recent price cut for Zepbound offered by Eli Lilly through its own direct-to-patient online platform.
Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe?
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients.
Solving Healthcare’s Provider Data Problem Starts with Interoperability
Break down the silos. Take control of your provider data.
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
Novo Nordisk’s monlunabant showed signs of neuropsychiatric side effects in a mid-stage diabetic kidney disease study, despite a drug design intended to favor hitting its target receptor in peripheral tissues rather than the brain. Neuro effects were also reported last year in a Phase 2 test of this pill in obesity.
New FDA Approval Adds Chronic Kidney Disease to Ozempic’s Label
Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.
Novo Nordisk Obesity Drug Shows 22% Weight Loss, But Lack of Safety Detail Is a Sticking Point
Novo Nordisk’s amycretin is a single molecule designed to bind to two targets to spark weight loss — a different approach than some of the pharma giant’s other efforts to develop next-generation obesity drugs. Analysts say the lack of safety and tolerability details make it difficult to fully assess the preliminary Phase 1b/2a results.
Do We Need Humans in the Loop? A Novo Nordisk Exec Weighs In (Video)
Thomas Senderovitz, senior vice president of data science at Novo Nordisk, challenges conventional notions about AI and the need for humans in the loop.
How Healthcare Leaders Reacted to the 15 Additional Drugs Selected for Medicare Negotiation Program
Many healthcare executives are applauding the list of additional drugs chosen for the Medicare Drug Price Negotiation Program, while some drug companies are opposing it.